Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

refractory multiple myeloma

Home/Tag:refractory multiple myeloma
1 06, 2014

All relapsed/refractory patients not created equal

Tags: , , , |5 Comments

As I mentioned earlier this week, there isn't much myeloma related activity at the American Society of Clinical Oncology (ASCO) until Monday.  That gives us a chance to review a couple of important things to look for when comparing one experimental therapy to another. Let's start with relapsed/refractory.  Someone who relapses isn't necessarily refractory (resistant)

14 09, 2013

Daratumumab ready for Stage 2 testing

Tags: , , , , |3 Comments

Always nice to report on a promising development.  Check-out this press release about the new rising myeloma therapy star, daratumumab, that I received last week: Genmab Announces New Study of Daratumumab in Double Refractory Myeloma Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma      -- After initial data read-out in Part

20 04, 2013

Big pharma isn’t all bad; 23 companies working hard to help relapsed myeloma patients

Tags: , |11 Comments

WOW!  Check-out how many companies are actively involved in developing chemotherapy for relapsed multiple myeloma patients as listed in a press release run in the Wall Street Journal April 18th: Companies Involved in Refractory Multiple Myeloma Therapeutics Development -- Bristol-Myers Squibb Company -- Johnson & Johnson -- Eli Lilly and Company -- GlaxoSmithKline plc --

1 04, 2012

Spot-on continuing ed program covers all of the myeloma therapy bases…

Tags: , , |0 Comments

Wow!  This continuing ed course for medical oncologists and hematologists is really interesting! The Challenge of Relapsed and/or Refractory Multiple Myeloma Complete with an accompanying power point presentation and lots of charts and slides, this Medscape Education program is both comprehensive and up-to-date, including reviews of carfilzomib, pomalidomide and elotuzumab. It may be a bit

27 11, 2010

Review About Using Anti-Bodies In Multiple Myeloma Therapy

Tags: , , , , |0 Comments

I have recieved a number of e-mail questions about the potential of using anti-bodies against multiple myeloma.  Here is an article I wrote in June following the large ASCO conference in Chicago which addressed this question:New Research Study Focuses On Antibodies To Stop Multiple MyelomaUpdate on another new anti-myeloma research study, post ASCO:Immunomedics doses first